Professor Toby Maher

Dr Maher runs an active clinical and translational research program and oversees a team of 13 trial staff, PhD fellows and post-doctoral scintists. Dr Maher's research interests include; basic and translational research into idiopathic pulmonary fibrosis; with a major focus on biomarker discovery, early phase clinical trials and the pre-clinical validation of putative targets and compound for the treatment of fibrosing lung disease.

Dr Maher's current funded research includes; 1) the PROFILE study, a longditudinal biomarker discovery program. In collaboration with Nottingham University the PROFILE study has now recruited over 500 individuals with IPF. 2) an MRC EME funded randomized controlled trial of Rituximab as a treatment for connective tissue disease associated interstitial lung disease - the RECITAL study and 3) and NIHR Clinician Scientists fellowship to evlute diagnostic biomarkers for fibrotic interstitial lung disease.

Dr Maher is the lead consultant for clinical trials in the Royal Brompton Interstitial Lung Disease Unit. He is currently UK principal investigator for a number of commercial studies of novel compounds being tested in trials for IPF and other interstitial lung diseases.

Dr Maher works closely with scientists at the Centre for Inflammation and Tissue Repair, University College London and has active collaborations with Nottingham University, University of East Anglia, National Jewish Hospital, Denver, US and McMaster University, Canada.